

News Releases

All Years



Search

GO

[Advanced Search](#)

Nov 15, 2019

Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

- Recommendations from Multidisciplinary Expert Panel on Anticoagulant Reversal and Replacement Guidance Published in Annals of Emergency Medicine -

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary...

Nov 6, 2019

Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

- Cerdulatinib Interim Phase 2a Data Highlight Efficacy and Safety Results in Patients with Heavily Pre-Treated T-Cell Malignancies and Follicular Lymphoma -

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will...

Nov 5, 2019

Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

- Andexxa®/Ondexxya® Net Product Revenues of \$35.7 million, a 32% Increase Over the Prior Quarter -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update. "We delivered another quarter of...

Nov 1, 2019

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2019, the grant...

Oct 28, 2019

Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding

- Effective Hemostasis Achieved in 82% of Evaluable Patients with Acute Gastrointestinal Bleeding -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new exploratory analysis of data from ANNEXA-4, the Company's Phase 3b/4 trial of its Factor Xa inhibitor...



Show 5 per



< 1 2 3 4 5 6 7 8 9 ... 49 >

page



<https://investors.portola.com/news-releases?l=5>